Published April 2018

This article presents the recommendations and suggestions for future research of an American Academy of Neurology (AAN) practice guideline on the efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS). Reaffirmed on October 19, 2024. Recommendations from current pract

Published April 2018

This article summarizes the findings and conclusions of an American Academy of Neurology (AAN) practice guideline on the efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS). A companion article presents the recommendations and suggestions for future research. Reaffi

Published September 2019

Some evidence suggests that infections may trigger MS relapses, increase MS radiologic and immunologic activity, and accelerate disease progression. Select reports link immunizations to clinical exacerbations of MS. Thus, it is understandable that patients with MS may have concerns about receiving r

Published January 2014

This guideline reviews the evidence and makes recommendations for identifying, diagnosing, and treating psychiatric disorders in individuals with MS. Reaffirmed on July 16, 2022. Endorsed by the American Association of Neuroscience Nurses, the Consortium of Multiple Sclerosis Centers, and the Inte

Published March 2014

The objective of this guideline is to develop evidence-based recommendations for complementary and alternative medicine (CAM) in multiple sclerosis (MS). Reaffirmed on February 25, 2023. Endorsed by the Consortium of Multiple Sclerosis Centers and the International Organization of Multiple Scleros